Clinical Trial Detail

NCT ID NCT02906059
Title Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors New York University School of Medicine
Indications

colorectal cancer

Therapies

Adavosertib + Irinotecan

Age Groups: adult senior

Additional content available in CKB BOOST